Novo Nordisk (NVO)
(Delayed Data from NYSE)
$118.01 USD
-1.06 (-0.89%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $116.24 -1.77 (-1.50%) 9:12 AM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.01 USD
-1.06 (-0.89%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $116.24 -1.77 (-1.50%) 9:12 AM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
Zacks News
AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?
by Zacks Equity Research
AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.
Can Merck (MRK) Pull Off a Surprise this Earnings Season?
by Zacks Equity Research
Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition.
Is Novo Nordisk (NVO) Stock a Solid Choice Right Now?
by Zacks Equity Research
Novo Nordisk (NVO) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
What Lies in Store for Glaxo (GSK) this Earnings Season?
by Zacks Equity Research
The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.
Why Did Radius Health (RDUS) Stock Plummet Today?
by Ryan McQueeney
Shares of Radius Health (RDUS) dropped more than 7.8% in early morning trading hours Monday after the company announced that Jesper Hoiland, a former top-ranking executive at Novo Nordisk (NVO), has been appointed its new president and chief executive officer.
Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod
by Arpita Dutt
All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.
Why You Should Add Novo Nordisk Stock to Your Portfolio
by Zacks Equity Research
Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.
Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion
by Zacks Equity Research
Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 17-2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk reduction in patients with type II diabetes.
Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug
by Zacks Equity Research
Novo Nordisk (NVO) announced positive results from the post-hoc analysis of the cardiovascular outcomes study, LEADER on Victoza.
Merck's Diabetes Drug Meets Primary Endpoint in Key Studies
by Zacks Equity Research
Merck & Co., Inc. (MRK) and partner Pfizer Inc. (PFE) announced that its pipeline candidate, ertugliflozin, met primary endpoints in two late stage studies evaluating ertugliflozin in adults with Type 2 diabetes.
Key FDA Events to Watch Out for in Jun 2017
by Arpita Dutt
Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.
Novo Nordisk's (NVO) Drug Gets FDA Approval for Hemophilia B
by Zacks Equity Research
Novo Nordisk (NVO) announced that the FDA has approved the Biologics License Application (BLA) for Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B.
5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio
by Zacks Equity Research
Campbell, CA -based VIVUS, Inc. (VVUS) is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs
AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk
by Zacks Equity Research
AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y
by Zacks Equity Research
Novo Nordisk A/S (NVO) reported first-quarter 2017 earnings of 58 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 53 cents by 9.4%.
6 FDA Events to Watch Out for in May 2017
by Arpita Dutt
Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.
Merck's Bid to Add Cardiovascular Data on Januvia Label Fails
by Zacks Equity Research
Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.
Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion
by Zacks Equity Research
Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.
Orexigen Inks Commercialization Deal for Contrave, Stock Up
by Zacks Equity Research
Orexigen Therapeutics, Inc.'s (OREX) announced that it has entered into a commercialization and distributorship agreement with Italian pharmaceutical company, Bruno Farmaceutici, for its obesity drug, Contrave.
Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays
by Zacks Equity Research
We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.
Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA
by Zacks Equity Research
Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International
Top Analyst Reports for Priceline, Schwab & NextEera Energy
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Priceline (PCLN), NextEra Energy (NEE) and Schwab (SCHW).
Novo Nordisk Inks Diabetes Deal with University of Oxford
by Zacks Equity Research
Novo Nordisk A/S (NVO) and University of Oxford announced a landmark research collaboration for the treatment of type II diabetes.
Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
by Zacks Equity Research
Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.